Skip to main content Back to Top
Advertisement

9/17/2019

Ethiodized Oil

Reason for the Shortage

    • Guerbet has Lipiodol injection available.[1]
    • Guerbet has transferred the manufacturing of Lipiodol injection to the US. As of March 2019, Lipiodol Ultra-Fluide is no longer being imported.[1]
    • Guerbet had Lipiodol injection in short supply due to manufacturing problems at Jubilant HollisterStier, the manufacturing site in Canada that supplies Lipiodol for Guerbet.[1-2]

Available Products

    • Lipiodol injection, Guerbet, 10 mL vial, NDC 67684-1901-02

Implications for Patient Care

    • Ethiodized oil is a lipophilic non-ionic iodinated contrast medium, derived from poppy seed oil.[3] Lipiodol is the only lipophilic non-ionic contrast media approved in the US.[3-4]
    • Ethiodized oil is labeled for use in patients undergoing hysterosalpingography or lymphography and for hepatic intra-arterial use for imaging tumors in patients with hepatocellular carcinoma.[3]
    • Ethiodized oil is also commonly used in chemoembolization procedures for the treatment of primary and secondary hepatic malignancies.[5-7]

References

    1. Guerbet. Personal communication. June 3, July 13, December 16, 2015; February 17, April 26, June 28, September 20, December 12, 2016; March 13, June 20, October 5 and 10, 2017; January 17, April 11, July 17, October 25, 2018; February 7, May 15, July 17, and September 17, 2019.
    2. Guerbet. Dear Healthcare Professional Letter. June 1, 2015. Available online at http://www.guerbet-us.com/fileadmin/user_upload/usa_home/customer_care_center/documents/June_1__2015_Lipiodol_Guerbet_DHP_Letter.pdf. Accessed June 2, 2015.
    3. Lipiodol (ethiodized oil) injection product information. Bloomington, IN: Guerbet, April 2014.
    4. Swanson D, Maywood C. Miscellaneous radiopaque contrast media. II. Hysterosalpingographic contrast media. In: Swanson D, Chilton H, Thrall J, eds. Pharmaceuticals in Medical Imaging. Radiopaque Contrast Media, Radiopharmaceuticals, Enhancement Agents for Magnetic Resonance Imaging and Ultrasound. New York, NY: MacMillan Publishing Co; 1990:227-236.
    5. American College of Radiology. ACR Appropriateness Criteria. Radiologic Management of Hepatic Malignancy, 2011: http://www.acr.org/~/media/ACR/Documents/AppCriteria/Interventional/RadiologicManagementHepaticMalignancy.pdf. Accessed June 2, 2015.
    6. Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs. Jun 2004;15(5):427-437.
    7. Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol. Feb 2006;17(2 Pt 1):217-223.

Updated

Updated September 17, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 3, 2015 by Erin R. Fox, PharmD, Director, Drug Information Service. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins